» Articles » PMID: 30581443

CD5, an Undercover Regulator of TCR Signaling

Overview
Journal Front Immunol
Date 2018 Dec 25
PMID 30581443
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

T cells are critical components of adaptive immunity. As such, their activation is regulated by the T cell receptor (TCR) that constantly scan peptides associated with major histocompatibility complexes (MHC). TCR engagement initiates a series of molecular events leading to cytokine secretion, proliferation, and differentiation of T cells. As a second coincident event, activation of co-stimulatory molecules, such as CD28, synergize with the TCR in order to prolong and/or amplify intracellular signals. With the recent advances in immunotherapies targeting T cells, co-inhibitory receptors are of growing interest for immunologists due to their potential modulatory properties on T cell functions. However, special attention should be dedicated to avoid unwanted clinical outcomes (1). In particular, Manichean categorization of receptors based on incomplete functional knowledge can lead to an over-simplistic view of complex cellular regulations. Thus, analysis of the functions that characterize these receptors in diverse physiological contexts remains essential for their rational use in therapeutic protocols. Here we focus on CD5, a transmembrane receptor that regulates T cell functions and development but remains poorly characterized at the molecular level. We will review its roles in physiological conditions and suggest potential molecular effectors that could account for CD5-dependent regulation of TCR signaling.

Citing Articles

Association between 91 circulating inflammatory proteins and the risk of glaucoma: A Mendelian randomization study.

Xu W, Fan Q, Meng Y, Nie Z, Sawut A, Xie S Sci Rep. 2025; 15(1):8876.

PMID: 40087334 DOI: 10.1038/s41598-025-92153-y.


TMEM41B is an endoplasmic reticulum Ca release channel maintaining naive T cell quiescence and responsiveness.

Ma Y, Wang Y, Zhao X, Jin G, Xu J, Li Z Cell Discov. 2025; 11(1):18.

PMID: 40038246 PMC: 11880246. DOI: 10.1038/s41421-024-00766-w.


Orthogonal transcriptional modulation and gene editing using multiple CRISPR-Cas systems.

Brokso A, Bendixen L, Famme S, Mikkelsen K, Jensen T, Bak R Mol Ther. 2024; 33(1):71-89.

PMID: 39563029 PMC: 11764084. DOI: 10.1016/j.ymthe.2024.11.024.


Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas.

Elghawy O, Cao M, Xu J, Landsburg D, Svoboda J, Nasta S Cancers (Basel). 2024; 16(19).

PMID: 39410047 PMC: 11476060. DOI: 10.3390/cancers16193430.


A novel bioinformatics pipeline for the identification of immune inhibitory receptors as potential therapeutic targets.

Singh A, Miranda Bedate A, von Richthofen H, Vijver S, van der Vlist M, Kuhn R Elife. 2024; 13.

PMID: 39377459 PMC: 11460946. DOI: 10.7554/eLife.92870.


References
1.
Orta-Mascaro M, Consuegra-Fernandez M, Carreras E, Roncagalli R, Carreras-Sureda A, Alvarez P . CD6 modulates thymocyte selection and peripheral T cell homeostasis. J Exp Med. 2016; 213(8):1387-97. PMC: 4986531. DOI: 10.1084/jem.20151785. View

2.
Brown M, Lacey E . A ligand for CD5 is CD5. J Immunol. 2010; 185(10):6068-74. PMC: 2996635. DOI: 10.4049/jimmunol.0903823. View

3.
Murphy M, Schnall R, Venter D, Barnett L, Bertoncello I, Thien C . Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol Cell Biol. 1998; 18(8):4872-82. PMC: 109072. DOI: 10.1128/MCB.18.8.4872. View

4.
Tarakhovsky A, Kanner S, Hombach J, Ledbetter J, Muller W, Killeen N . A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science. 1995; 269(5223):535-7. DOI: 10.1126/science.7542801. View

5.
Davidson D, Zhong M, Pandolfi P, Bolland S, Xavier R, Seed B . The Csk-Associated Adaptor PAG Inhibits Effector T Cell Activation in Cooperation with Phosphatase PTPN22 and Dok Adaptors. Cell Rep. 2016; 17(10):2776-2788. PMC: 5656005. DOI: 10.1016/j.celrep.2016.11.035. View